Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 4/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.53 |
| ▸ | TACR1 | P25103 | 5/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL339983 | 0.89 | TACR1 (0.61) | SLC6A2SLC6A4SLC6A3KCNH2TACR1 | |
| SCHEMBL341134 | 0.84 | SLC6A2 (0.53) | SLC6A2SLC6A4SLC6A3KCNH2TACR1 | |
| SCHEMBL342224 | 0.83 | HTR2A (0.55) | SLC6A2SLC6A4SLC6A3KCNH2TACR1 | |
| SCHEMBL339704 | 0.82 | TACR1 (0.55) | SLC6A2SLC6A4SLC6A3KCNH2TACR1 | |
| SCHEMBL341681 | 0.82 | TACR1 (0.49) | SLC6A2SLC6A4SLC6A3KCNH2TACR1 | |
| SCHEMBL4208221 | 0.81 | SLC2A1 (0.48) | OPRM1ALDH1A1MEN1KMT2AHTR2A | |
| SCHEMBL342516 | 0.80 | TACR1 (0.53) | SLC6A2SLC6A4SLC6A3KCNH2TACR1 | |
| SCHEMBL28069304 | 0.80 | SLC6A2 (0.51) | SLC6A2SLC6A4SLC6A3KCNH2TACR1 | |
| SCHEMBL340465 | 0.79 | SLC6A2 (0.51) | SLC6A2SLC6A4SLC6A3KCNH2TACR1 | |
| SCHEMBL341939 | 0.79 | ALOX5 (0.60) | SLC6A2SLC6A4SLC6A3KCNH2OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1787984-B1 | AZACYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF SEROTONIN RELATED DISEASES | ACADIA PHARM INC (US) | 2016-10-19 | — | — | EP | claimed |
| US-20140350064-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AN AMPK ACTIVATOR AND A SEROTONERGIC AGENT AND METHODS OF USE THEREOF | ALS MOUNTAIN LLC | 2014-11-27 | — | — | US | claimed |
| US-20120183600-A1 | NOVEL COMPOSITION FOR TREATING METABOLIC SYNDROME AND OTHER CONDITIONS | CHEN CHIEN-HUNG (US) | 2012-07-19 | — | — | US | claimed |
| JP-4664564-B2 | — | — | 2011-04-06 | — | — | JP | claimed |
| EP-1787984-A2 | AZACYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF SEROTONIN RELATED DISEASES | Arcadia Pharmaceuticals Inc. (US) | 2007-05-23 | — | — | EP | claimed |
| EP-1263729-B1 | AZACYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF SEROTONIN RELATED DISEASES | ACADIA PHARM INC (US) | 2006-12-20 | — | — | EP | claimed |
| US-20060194778-A1 | Serotonin receptor antagonist; psychological disorders; side effect reduction | ACADIA PHARMACEUTICALS, INC. | 2006-08-31 | — | — | US | claimed |
| US-20050014757-A1 | Azacyclic compounds | ANDERSSON CARL-MAGNUS A (DK) | 2005-01-20 | — | — | US | claimed |
| US-6815458-B2 | NERVOUS SYSTEM DISORDERS | ACADIA PHARMACEUTICALS, INC | 2004-11-09 | — | — | US | claimed |
| US-20030220316-A1 | Azacyclic compounds | ACADIA PHARMACEUTICALS INC. | 2003-11-27 | — | — | US | claimed |
| JP-2003531829-A | — | — | 2003-10-28 | — | — | JP | claimed |
| CN-1443167-A | Azacyclo compounds for the treatment of 5-hydroxytryptamine related disorders | ACADIA PHARM INC (US) | 2003-09-17 | — | — | CN | claimed |
| EP-1263729-A1 | AZACYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF SEROTONIN RELATED DISEASES | Acadia Pharmaceuticals Inc. (US) | 2002-12-11 | — | — | EP | claimed |
| US-20020004513-A1 | Azacyclic compounds | ACADIA PHARMACEUTICALS INC. | 2002-01-10 | — | — | US | claimed |
| WO-2001066521-A1 | AZACYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF SEROTONIN RELATED DISEASES | ACADIA PHARMACEUTICALS, INC. (US) | 2001-09-13 | — | — | WO | claimed |
| US-9765053-B2 | Methods of treatment using selective 5-HT2A inverse agonists | ACADIA PHARMACEUTICALS INC. (US) | 2017-09-19 | — | — | US | disclosed |
| US-20170165273-A9 | METHODS OF TREATMENT USING SELECTIVE 5-HT2A INVERSE AGONISTS | ANDERSSON CARL-MAGNUS A (DK) | 2017-06-15 | — | — | US | disclosed |
| EP-1263729-A1 | AZACYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF SEROTONIN RELATED DISEASES | Acadia Pharmaceuticals Inc. (US) | 2002-12-11 | — | — | EP | disclosed |
| US-20020004513-A1 | Azacyclic compounds | ACADIA PHARMACEUTICALS INC. | 2002-01-10 | — | — | US | disclosed |
| WO-2001066521-A1 | AZACYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF SEROTONIN RELATED DISEASES | ACADIA PHARMACEUTICALS, INC. (US) | 2001-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220316-A1 | Azacyclic compounds | HTR6, TPMT, HNMT | SLC6A2 48/4885SLC6A4 35/4885SLC6A3 177/4885 |
| US-20020004513-A1 | Azacyclic compounds | HTR6, TPMT, HNMT | SLC6A2 48/4885SLC6A4 35/4885SLC6A3 177/4885 |
| US-20050014757-A1 | Azacyclic compounds | HTR6, TPMT, HNMT | SLC6A2 48/4885SLC6A4 35/4885SLC6A3 177/4885 |
| US-20170165273-A9 | METHODS OF TREATMENT USING SELECTIVE 5-HT2A INVERSE AGONISTS | HTR2A, HTR5A, HTR3B | SLC6A2 32/4885SLC6A4 22/4885SLC6A3 90/4885 |
| US-20060194778-A1 | Serotonin receptor antagonist; psychological disorders; side effect reduction | HTR2A, HTR1A, HTR1B | SLC6A2 43/4885SLC6A4 23/4885SLC6A3 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.